drugset / Trial / NCT00073437

A Study of Infliximab in Patients With Sarcoidosis

NCT00073437

Phase 3 Completed 139 enrolled Centocor, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Sarcoidosis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

Timeline

Start
2003-10
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 3 mg/kg
Subject Infliximab Monoclonal antibody 5 mg/kg

Indications